Head and Neck Neoplasm — Variants & evidence

Head and Neck Neoplasm — Variants & evidence · CancerIndex

Variants & evidence

Curated clinical evidence by variant and therapy

252 evidence items mapped to this entity or its descendants, grouped by molecular profile, then therapy. 50 items per page.

civicCuratedShowing 251–252 of 252 evidence items (2 on this page mapped to a descendant entity) · levels, directions and significance as curated at the source; each row links to its CIViC record.

Therapy	Cancer	Type	Level	Direction · significance	Rating (1–5)	Status	Evidence	Source
RET Mutation + RET Fusion2
Pralsetinib	Malignant Thyroid Gland Neoplasm	Predictive	A	Supports Sensitivity Response	4	submitted	EID11267 In this multi-cohort, open-label, phase 1/2 study, 122 patients with RET-mutant medullary and 20 with RET fusion-positive thyroid cancers were started on pralsetinib dosed at 400 mg once daily. Overal… (full text at CIViC) PMID 34118198 · Subbiah et al., 2021 · Open in CIViC	civic
Selpercatinib	Malignant Thyroid Gland Neoplasm	Predictive	A	Supports Sensitivity Response	4	rejected	EID11268 In this phase 1/2 study, 55 patients with RET-mutant medullary thyroid cancer who had previously received vandetanib and/or cabozantinib, 88 patients with the same disease who had not previously recei… (full text at CIViC) PMID 32846061 · Wirth et al., 2020 · Open in CIViC	civic

Data updated 13 hours agoSource updated unknownsource: civic (CC0)

Evidence levels, directions and ratings are those assigned by CIViC curators. "Submitted" items have not completed curation review. This is not treatment guidance.